Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
The MHRA approved it on 11 June 2026
The sites invert the usual practice of medicine by turning the act of prescribing drugs into a service
Functional targeting of cancer-associated fibroblasts (CAFs) using a combination of DFO and follistatin-like protein 1 (FSTL1) -neutralizing antibody significantly alleviated CAF-induced natural killer cell (NK cell) ferroptosis and boosted the cytotoxicity of NK cells against GC [104]
Redox Biol 2023;63:102749.ArticlePubMedPMC 50
US$ 23.27
US$ 26.59
US$ 23.87
